RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000133.xml
Gastroenterologie up2date 2021; 17(01): 11-14
DOI: 10.1055/a-1176-3824
DOI: 10.1055/a-1176-3824
SOP / Arbeitsablauf
SOP CRS und HIPEC für peritoneale Metastasen mit gastrointestinalem Ursprung
Die peritoneal metastasierten Malignome des Gastrointestinaltrakts stellen eine therapeutische Herausforderung dar. Die makroskopisch komplette zytoreduktive Chirurgie (CRS) gefolgt von hyperthermer intraperitonealer Chemotherapie (HIPEC) ermöglicht eine substanzielle Verbesserung des Outcomes bei hochselektionierten Patienten gegenüber alleiniger systemischer Chemotherapie [1]. Diese SOP beschreibt die Auswahlkriterien und das Vorgehen.
Schlüsselwörter
komplette zytoreduktive Chirurgie - hypertherme intraperitoneale Chemotherapie - peritoneal metastasierte gastrointestinale Tumoren - Pseudomyxoma peritonei - PeritonealkarzinosePublikationsverlauf
Artikel online veröffentlicht:
08. März 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Huang C, Min Y, Wang S. et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget 2017; 8: 55657-55683
- 2 AWMF. S3-Leitlinie Kolorektales Karzinom. 2019. Im Internet (Stand: 01.10.2020): http://www.awmf.org/uploads/tx_szleitlinien/021-007OLl_S3_Kolorektales-Karzinom-KRK_2019-01.pdf
- 3 AWMF. S3-Leitlinie Magenkarzinom. 2019. Im Internet (Stand: 01.10.2020): http://www.awmf.org/uploads/tx_szleitlinien/032-009OLl-KF_Magenkarzinom_2019-01.pdf
- 4 Esquivel J, Sticca R, Sugarbaker P. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement. Ann Surg Oncol 2007; 14: 128-133 doi:10.1245/s10434-006-9185-7
- 5 Cavaliere F, De Simone M, Virzì S. et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol 2011; 37: 148-154 doi:10.1016/j.ejso.2010.10.014
- 6 Blaj S, Nedelcut S, Mayr M. et al. Re-operations for early postoperative complications after CRS and HIPEC: indication, timing, procedure and outcome. Langenbecks Arch Surg 2019; 404: 541-546 doi:10.1007/s00423-019-01808-8
- 7 Quenet F, Elias D, Roca L. et al. UNICANCER-GI Group and the French BIG-Renape Group. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol 2018; 36 (18 Suppl.): LBA3503
- 8 Bakkers C, van Erning FN, Rovers KP. et al. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study. Eur J Surg Oncol 2020; 46: 1902-1907 doi:10.1016/j.ejso.2020.04.018
- 9 Moran B, Cecil T, Chandrakumaran K. et al. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Dis 2015; 17: 772-778 doi:10.1111/codi.12975
- 10 Benhaim L, Faron M, Gelli M. et al. Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei. Surg Oncol 2019; 29: 78-83 doi:10.1016/j.suronc.2019.03.004
- 11 Glockzin G, Zeman F, Kroner RS. et al. Perioperative systemic chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastases: Results of the prospective multicenter phase 2 COMBATAC trial. Clin Colorectal Cancer 2018; 17: 285-296 doi:10.1016/j.clcc.2018.07.011
- 12 Piso P, Stierstorfer K, Gerken M. et al. Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer. Int J Colorectal Dis 2018; 33: 1559-1567
- 13 Bonnot PE, Piessen G, Kepenekian V. et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): A propensity score analysis. J Clin Oncol 2019; 37: 2028-2040 doi:10.1200/JCO.18.01688
- 14 Rau B, Brandl A, Piso P. et al. Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer 2020; 23: 11-22 doi:10.1007/s10120-019-00978-0